<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="133">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05159414</url>
  </required_header>
  <id_info>
    <org_study_id>NE_RTN_001</org_study_id>
    <nct_id>NCT05159414</nct_id>
  </id_info>
  <brief_title>Study of Application of Pulse Electrical Stimulation Around Eye in Glaucoma Patients</brief_title>
  <official_title>A Single Center, Open-label, Exploratory Study to Evaluate the Efficacy and Safety of the Application of Pulse Electrical Stimulation Around the Eye in Glaucoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nu Eyne Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nu Eyne Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the efficacy and safety of applying pulse electrical stimulation&#xD;
      around eyes of glaucoma patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Duration of study period(per participant): Screening period(0-4weeks), Intervention&#xD;
      period(16weeks) Patient needs to visit site at least 5 times(Screening, V2, V3, V4, V5). V2&#xD;
      can be done with screening visit. Visit 3, 4, 5 is 2weeks, 6weeks, and 16weeks after visit&#xD;
      2(Baseline).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in intraocular pressure</measure>
    <time_frame>baseline, 2, 6, 12, 16 weeks</time_frame>
    <description>Check the change of intraocular pressure in the baseline, 2, 6, 12, 16 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in visual acuity</measure>
    <time_frame>baseline, 2, 6, 12, 16 weeks</time_frame>
    <description>Check the change of visual acuity in the baseline, 2, 6, 12, 16 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in mean deviation (MD)</measure>
    <time_frame>baseline, 2, 6, 12, 16 weeks</time_frame>
    <description>Check the change of mean deviation(MD) in the baseline, 2, 6, 12, 16 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in pattern standard deviation(PSD)</measure>
    <time_frame>baseline, 2, 6, 12, 16 weeks</time_frame>
    <description>Check the change of pattern standard deviation(PSD) in the baseline, 2, 6, 12, 16 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in visual field index(VFI)</measure>
    <time_frame>baseline, 2, 6, 12, 16 weeks</time_frame>
    <description>Check the change of visual field index(VFI) in the baseline, 2, 6, 12, 16 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in parapapillary retinal nerve fiber layer thickness (RNFLT) using optical coherence tomography(OCT)</measure>
    <time_frame>baseline, 6, 16 weeks</time_frame>
    <description>Check the change of parapapillary retinal nerve fiber layer thickness(RNFLT) in the baseline, 6, 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Laminar cribrosa (LC) depth using optical coherence tomography(OCT)</measure>
    <time_frame>baseline, 6, 16 weeks</time_frame>
    <description>Check the change of Laminar cribrosa(LC) depth in the baseline, 6, 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in macular ganglion cell-inner plexiform layer thickness (GCIPLT) using optical coherence tomography(OCT)</measure>
    <time_frame>baseline, 6, 16 weeks</time_frame>
    <description>Check the change of macular ganglion cell-inner plexiform layer thickness(GCIPLT) in the baseline, 6, 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in circumpapillary vessel density (cpVD) using Optical coherence tomography angiography(OCT-A)</measure>
    <time_frame>baseline, 6, 16 weeks</time_frame>
    <description>Check the change of circumpapillary vessel density(cpVD) in the baseline, 6, 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in macular vessel density (mVD) using Optical coherence tomography angiography(OCT-A)</measure>
    <time_frame>baseline, 6, 16 weeks</time_frame>
    <description>Check the change of macular vessel density(mVD) in the baseline, 6, 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in N95 amplitude using pattern Electroretinogram(ERG)</measure>
    <time_frame>baseline, 6, 16 weeks</time_frame>
    <description>Check the change of N95 amplitude in the baseline, 6, 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in latency using pattern Electroretinogram(ERG)</measure>
    <time_frame>baseline, 6, 16 weeks</time_frame>
    <description>Check the change of latency in the baseline, 6, 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Glaucoma Quality of Life-15 (GQL-15)</measure>
    <time_frame>baseline, 6, 16 weeks</time_frame>
    <description>Check the change of Glaucoma Quality of Life-15(GQL-15) score in the baseline, 6, 16 weeks</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Glaucoma patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duration of study period(per participant): Screening period(0-4weeks), Intervention period(16weeks) Patient needs to visit site at least 5 times(Screening, V2, V3, V4, V5). V2 can be done with screening visit. Visit 3, 4, 5 is 2weeks, 6weeks, and 16weeks after visit 2(Baseline).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pulse Electrical Stimulation</intervention_name>
    <description>Pulse Electrical Stimulation Patients wear our clinical trial device 30mins once a day for 16weeks.</description>
    <arm_group_label>Glaucoma patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must be 19 to 75 years of age, at the time of screening&#xD;
&#xD;
          -  Patients with normal tension glaucoma or open angle glaucoma&#xD;
&#xD;
          -  Patients with best-corrected visual acuity of 20/40 or more&#xD;
&#xD;
          -  Patients whose Mean Deviation(MD) value of visual field test is -6dB or less&#xD;
&#xD;
          -  Patients who have stable eye pressure of less than 20mmHg over the past 2 months&#xD;
&#xD;
          -  If glaucoma treatment is in progress, the type, dose, and form of drug for treatment&#xD;
             are stable for more than 2 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A person who has no pregnancy plan during the clinical trial period and has agreed to&#xD;
             an effective contraceptive plan for Women of child bearing potential(WOCBP)&#xD;
&#xD;
          -  Women of non-child bearing potential(WONCBP) must meet at least one of the following&#xD;
             criteria:&#xD;
&#xD;
               1. Postmenopausal women who are at least 45 years old and had no menses for 24&#xD;
                  consecutive months&#xD;
&#xD;
               2. A woman who underwent hysterectomy of bilateral ovarian resection recorded by a&#xD;
                  doctor&#xD;
&#xD;
          -  All other female patients will be considered WOCBP.&#xD;
&#xD;
          -  A person who voluntarily agreed to participate in this clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Youn Hye Jo, Ph. D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Konkuk University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinho Jung</last_name>
    <phone>+821083113509</phone>
    <email>jinho.jung@nueyne.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nayoung Kang</last_name>
    <phone>+821073734097</phone>
    <email>nayoung.kang@nueyne.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Ophthalmology, Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Youn Hye Jo, Ph. D., MD.</last_name>
      <email>20200181@kuh.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Youn Hye Jo, Ph. D., MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 2, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

